Merck KGaA, Research & Development, Drug Metabolism & Pharmacokinetics New Biological Entities, Darmstadt, 64293, Germany.
Celerion Switzerland AG, Bioanalytical Services, Fehraltorf, 8320, Switzerland.
Bioanalysis. 2024;16(17-18):915-921. doi: 10.1080/17576180.2024.2376950. Epub 2024 Aug 5.
The European Bioanalysis Forum, in collaboration with several key industry stakeholders, has recently led discussions that address international immunogenicity guidance documents, specifically the three tier approach for immunogenicity testing strategies, after more than 20 years of experience with biotherapeutics. As part of this, the strategy and methods used to assess drug tolerance across all immunogenicity assays are challenged, emphasizing that bioanalytical scientists need to consider the context-of-use of each assay. Here, recommendations for drug tolerance assessments, driven by strong scientific rationale and subject to reevaluation as needed, are provided. This includes carefully considering the drug and positive control concentrations considered to be appropriate and which tiers are most relevant for performing drug tolerance assessments.
欧洲生物分析论坛(European Bioanalysis Forum)与多个主要行业利益相关者合作,最近对国际免疫原性指导文件进行了讨论,特别是针对免疫原性检测策略的三层方法,这是在具有 20 多年生物治疗经验之后进行的。作为其中的一部分,用于评估所有免疫原性检测中药物耐受性的策略和方法受到了挑战,强调生物分析科学家需要考虑每个检测的使用情况。在这里,根据强有力的科学原理提供了药物耐受性评估的建议,并根据需要进行重新评估。这包括仔细考虑被认为合适的药物和阳性对照浓度,以及进行药物耐受性评估最相关的层次。